The relationship between ischemia-modified albumin/ albumin ratio levels and disease severity in COVID-19 patients

Basit Öğe Kaydı
dc.authorscopusid57194695019
dc.authorscopusid57196329897
dc.authorscopusid58249131800
dc.authorscopusid57191692583
dc.authorscopusid56187185800
dc.authorscopusid6602113917
dc.authorscopusid55172463000
dc.contributor.authorAksit M.
dc.contributor.authorAksit M.Z.
dc.contributor.authorKazar M.
dc.contributor.authorCaliskan T.
dc.contributor.authorSenger S.S.
dc.contributor.authorAkar H.
dc.contributor.authorErsan G.
dc.date.accessioned2024-03-09T19:39:59Z
dc.date.available2024-03-09T19:39:59Z
dc.date.issued2023
dc.departmentİzmir Bakırçay Üniversitesien_US
dc.description.abstractObjectives: In COVID-19 infection, oxidative stress occurs with the abnormal release of proinflammatory cytokines and the disruption of the balance between oxidants and antioxidants. In our study, we aimed to investigate the relationship between ischemia-modified albumin (IMA), a biomarker of oxidative stress, and the severity of the disease in hospitalized COVID-19 patients. Methods: One hundred and twenty-four hospitalized patients with a diagnosis of COVID-19 were included in the study. These patients were divided into critical and non-critical groups. Serum IMA levels were measured by the colorimetric albumin cobalt-binding method. The IMA-albumin ratio (IMAR) was calculated by dividing IMA values by albumin values. Results: The IMA and IMAR values of the critical COVID-19 group were statistically significantly higher than the non-critical group. In the multivariate analysis, the two variables IMAR and glucose were found to have the most important role in the severity of COVID-19 disease. For IMAR, the area under the ROC curve had a value of 0.725 (95% confidence interval 0.636–0.803). Conclusion: IMA and IMAR levels of the critical group were found to be higher than the non-critical group in COVID patients. We have observed that IMAR levels are associated with the severity of the disease and that IMAR is an independent prognostic risk factor for the disease. © 2023, Kare Publishing. All rights reserved.en_US
dc.identifier.doi10.14744/ijmb.2023.74436
dc.identifier.endpage149en_US
dc.identifier.issn2587-2362
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85171300361en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage143en_US
dc.identifier.urihttps://doi.org/10.14744/ijmb.2023.74436
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1608
dc.identifier.volume6en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKare Publishingen_US
dc.relation.ispartofInternational Journal of Medical Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAlbumin; COVID-19; IMAR; ischemia-modified albumin; oxidative stressen_US
dc.titleThe relationship between ischemia-modified albumin/ albumin ratio levels and disease severity in COVID-19 patientsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1608.pdf
Boyut:
259.27 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu